Clinical Trials
88 trialsReduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
Duke University
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Medical College of Wisconsin
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
ACHIEVE
TC Biopharm
5
Institut Curie
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Ensoma
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Weill Medical College of Cornell University
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Cellphire Therapeutics, Inc.
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
GVAX vs. Placebo for MDS/AML After Allo HSCT
Dana-Farber Cancer Institute
T-cell Depleted Alternative Donor Transplantation
Wake Forest University Health Sciences
A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia
Memorial Sloan Kettering Cancer Center
MSC and HSC Coinfusion in Mismatched Minitransplants
University of Liege
The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients
University of Chicago
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
CTI BioPharma
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
M.D. Anderson Cancer Center
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
Fred Hutchinson Cancer Center
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
NYU Langone Health
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
Post Transplant Donor Lymphocyte Infusion
Masonic Cancer Center, University of Minnesota
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
St. Petersburg State Pavlov Medical University
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
SAMBA
GWT-TUD GmbH
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
M.D. Anderson Cancer Center
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes
Wake Forest University Health Sciences
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic Syndromes
Wake Forest University Health Sciences
Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies
Weill Medical College of Cornell University
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
Medical University of South Carolina
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Massachusetts General Hospital
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
Massachusetts General Hospital
Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS
Stanford University
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Masonic Cancer Center, University of Minnesota
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
Masonic Cancer Center, University of Minnesota
Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
St. Jude Children's Research Hospital
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Fred Hutchinson Cancer Center